Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 1712

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 9
Chunk 1712
---

    Non-vested at December 31, 2023 
     113,429  
    $22.68 

The
total number of options granted during the years ended December 31, 2024 and 2023 was 684,000 and 158,670, respectively.
The exercise price for these options was $0.73, $1.30 or $22.68 per share. There was an intrinsic value of $0 and
$0 as of December 31, 2024 and 2023, respectively.

The
Company recognized stock-based compensation expense related to option vesting amortization of $1,455,561 and $1,733,233 for
the years ended December 31, 2024 and 2023, respectively, which is included in general and administrative expenses in the consolidated
statements of operations.

As
of December 31, 2024, the unamortized stock option expense was $1,295,319. As of December 31, 2024, the weighted average period
for the unamortized stock compensation to be recognized is 1.75 years.

Warrants

The
following is an analysis of the stock warrant grant activity:

 Schedule
of analysis of the stock warrant grant

    Weighted Average  
    Weighted Average 

    Number of Shares  
    Exercise Price  
    Remaining Life 

    Stock Warrants 

    Outstanding December 31, 2023 
     —  
    $—  
     — 

    Granted 
     55,000  
    $7.50  
     4.99 

    Expired 
     —  
    $—  
     — 

    Exercised 
     —  
    $—  
     — 

    Outstanding December 31, 2024 
     55,000  
    $7.50  
     4.13 

    Exercisable December 31, 2024 
     55,000  
    $7.50  
     4.38 

    F-24 

A
summary of the status of the Company’s nonvested warrants as of December 31, 2024, and changes during the year ended December
31, 2024, is presented below:

 Schedule